What is Bristle?
Bristle operates at the intersection of biotechnology and consumer wellness, offering the world's first at-home oral microbiome saliva test. The company's platform is engineered to identify specific bacterial profiles associated with common oral health issues, including gum disease, cavities, and halitosis. By providing users with personalized care plans based on their unique biological data, Bristle empowers individuals to take a proactive stance on their oral hygiene. The company serves both health-conscious consumers seeking data-driven wellness solutions and dental professionals looking to integrate precision diagnostics into their clinical practice. Through its convenient testing kits and rapid turnaround times, Bristle is effectively democratizing access to complex microbiome analysis.
How much funding has Bristle raised?
Bristle has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Y Combinator, Anne Wojcicki, and Initialized Capital
Key Investors in Bristle
Y Combinator
A premier startup accelerator and venture capital firm that provides seed funding and mentorship to early-stage companies across diverse technology sectors.
Initialized Capital
A venture capital firm dedicated to supporting seed stage founders across various sectors including health, artificial intelligence, and consumer technology.
Anne Wojcicki
A prominent entrepreneur and investor known for her leadership in the genomics and personalized health testing industry.
What's next for Bristle?
With the successful completion of this major enterprise-level funding, Bristle is poised to accelerate its product development roadmap and enhance its diagnostic capabilities. The strategic focus will likely shift toward scaling its laboratory infrastructure to meet increasing demand and expanding its footprint in the preventative healthcare market. Furthermore, the company is expected to deepen its partnerships with dental practitioners, fostering a more integrated ecosystem where at-home testing informs professional clinical interventions. As Bristle continues to refine its proprietary algorithms, the firm is well-positioned to capture a significant share of the burgeoning oral microbiome market, ultimately shifting the paradigm from reactive treatment to proactive, data-driven oral health management.
See full Bristle company page
